Feb 6 (Reuters) - Labcorp LH.N forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.
Demand for diagnostic tests has grown in recent quarters as more people, especially older adults, caught up on procedures after the pandemic.
The company expects annual revenue in the range of $13.88 billion to $14.05 billion, above analysts' average estimate of $13.8 billion, according to data compiled by LSEG.
It expects its 2025 adjusted profit to be between $15.60 and $16.40 per share, with its midpoint in line with estimates of $16.02 per share.
Peer Quest Diagnostics DGX.N also beat Wall Street estimates for fourth-quarter profit and revenue last week, helped by a robust appetite for its diagnostic tests.
The company's fourth-quarter sales rose 9.8% to $3.33 billion, beating analysts' average estimate of $3.31 billion.
Sales in its smaller biopharma laboratory services unit, which offers contract research facilities for biopharmaceutical companies, rose 10.4% to $767 million.
On an adjusted basis, Labcorp posted a profit of $3.45 per share in the quarter ended December 31, above estimates of $3.39.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。